N-[2-(3,4-dimethoxyphenyl)ethyl]-4,7,7-trimethyl-2,3-dioxobicyclo[2.2.1]heptane-1-carboxamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: N-[2-(3,4-dimethoxyphenyl)ethyl]-4,7,7-trimethyl-2,3-dioxobicyclo[2.2.1]heptane-1-carboxamide
• 化学式: C₂₁H₂₇NO₅
• 分子量: 373.4
• InChiKey: WKJZKNFGZORWFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  81.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
  申请人：onepharm Research & Development GmbH

  公开号：EP2036548A1

  公开（公告）日：2009-03-18

  The present invention relates to the use of an 11-β-HSD-type 1 and/or type 2 inhibitor for the manufacture of a pharmaceutical agent for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage.

  本发明涉及使用 11-β-HSD 1 型和/或 2 型抑制剂制造药剂，以预防和/或治疗炎症诱导和/或免疫介导的骨和/或软骨损失。
• Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.
  申请人：OntoChem GmbH

  公开号：EP2243494A1

  公开（公告）日：2010-10-27

  A treatment using a hydroxysteroid dehydrogenase reductase inhibitor combined with a mineralocorticoid receptor antagonist is provided which overcomes the problem that manipulating cortisol levels by a single compound therapy induces other pathologies or side effects, while the original condition that required treatment is ameliorated.

  提供了一种使用羟基类固醇脱氢酶还原酶抑制剂与矿物皮质激素受体拮抗剂相结合的治疗方法，该方法克服了通过单一化合物疗法控制皮质醇水平会诱发其他病症或副作用的问题，而需要治疗的原有病症却得到了改善。
• 11Beta -Hydroxysteroid Dehydrogenases
  申请人：Wilckens Thomas

  公开号：US20080153791A1

  公开（公告）日：2008-06-26

  The present invention relates to novel 11β-HSD inhibitors as well as to the use of 11 β-HSD inhibitors for the manufacture of pharmaceutical agents for the prevention and/or treatment of metabolic diseases, cancer, cell proliferation, glaucoma, diseases associated with abnormal growth hormone secretion as well as wound healing disorders.
• PREVENTION AND TREATMENT OF INFLAMMATION-INDUCED AND/OR IMMUNE-MEDIATED BONE LOSS
  申请人：WILCKENS Thomas

  公开号：US20110275584A1

  公开（公告）日：2011-11-10

  The present invention relates to the use of an 11-β-HSD-type 1 and/or type 2 inhibitor for the manufacture of a pharmaceutical agent for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage.
• [EN] PHARMACEUTICAL COMPOSITION, COMPRISING A STEROID-DEHYDROGENASE-REDUCTASE INHIBITOR, AND A MINERALOCORTICOID RECEPTOR ANTAGONIST<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE REDUCTASE DÉSHYDROGÉNASE HYDROXYSTÉROÏDE, ET UN ANTAGONISTE DU RECEPTEUR MINERALOCORTICOÏDE
  申请人：ONTOCHEM GMBH

  公开号：WO2010121814A1

  公开（公告）日：2010-10-28

  A treatment using a hydroxysteroid dehydrogenase reductase inhibitor combined with a mineralocorticoid receptor antagonist is provided which overcomes the problem that manipulating Cortisol levels by a single compound therapy induces other pathologies or side effects, while the original condition that required treatment is ameliorated.